Loading clinical trials...
Loading clinical trials...
Inhibitors of the programmed cell death protein 1 (PD-1)/PD-L1 immune checkpoint signaling pathway are already approved in the treatment of various tumor entities in relapsed or metastatic stages. Dif...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
University of Erlangen-Nürnberg Medical School
NCT05967689 · Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
NCT07646288 · VATS, Respiratory Muscles, and more
NCT07489066 · Carcinoma, Non-Small-Cell Lung, and more
NCT07369596 · Non Small Cell Lung Carcinoma NSCLC
NCT07431281 · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, and more
Department of Radiation Oncology, Universitätsklinikum Erlangen
Erlangen, Bavaria
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions